about
Engineering opportunities in cancer immunotherapyNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyCell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine PlatformMaterials based tumor immunotherapy vaccinesEngineering cell-cell signalingModulation of the tumor microenvironment for cancer treatment: a biomaterials approachImaging and nanomedicine in inflammatory atherosclerosisRepositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent.Recent advances and novel treatment paradigms in acute lymphocytic leukemiaNew Bioengineering Breakthroughs and Enabling Tools in Regenerative MedicineTumor lysing genetically engineered T cells loaded with multi-modal imaging agentsTowards programming immune tolerance through geometric manipulation of phosphatidylserine.Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles.Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses.Nanoparticle approaches against bacterial infectionsBiomaterials for nanoparticle vaccine delivery systems.Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesiclesOvercoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug deliveryModulating antibacterial immunity via bacterial membrane-coated nanoparticlesTherapeutic Vaccine Strategies against Human Papillomavirus.6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Supramolecular peptide vaccines: tuning adaptive immunity.Impact of molecular weight on the intrinsic immunogenic activity of poly(beta amino esters).Intrinsic immunogenicity of rapidly-degradable polymers evolves during degradationImaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's ToolboxConjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapyNanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection.Nanoparticle-detained toxins for safe and effective vaccination.Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination.Engaging adaptive immunity with biomaterialsCoordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.Designing regenerative biomaterial therapies for the clinic.Engineering synthetic vaccines using cues from natural immunity.T cell-based targeted immunotherapies for patients with multiple myeloma.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.Nanomedicines for renal disease: current status and future applications
P2860
Q26776373-A54830E1-0996-4FAD-B5F1-973BC5C3039BQ26782566-537DAC9A-F21A-4AAE-BED1-5496573EFE1BQ26784233-BFE627FC-33ED-448A-8EF7-AC338E7DE157Q26824135-F8A3DC65-0AAD-4F72-87DC-003AF797D4A9Q26992234-9E53C7C5-69D0-4567-A7A9-4931B1B5AD6DQ26996790-0BA45A01-EB86-43B3-B30A-59CAF3A576ABQ27002916-6FD812D7-E991-47B9-926C-B35E811FE6C9Q27327281-9E29B70A-3A46-43BC-A63B-732C92318BDEQ28078076-3179CD57-5EF5-4480-BDC9-1B4195F08F30Q30354756-E2F6B5FB-D6FB-4A11-8C62-8E57B70FEC60Q30441151-97439DC2-792E-46E4-AA58-192933938871Q30751004-D139C0D1-BCD5-48B6-8E7A-EF879A68B063Q30877907-76F824F2-64E5-472F-A5E5-1FF8C002BD3FQ34145500-B54C9163-CB96-4BA8-B5EE-89EFE49739E2Q34339159-EF7DE3B2-6A2F-48B8-8B4E-1ED2E3B50E72Q34345012-1F91CF04-2286-4B35-AB74-D6CD4E7B4B64Q34576021-DC467931-5ECA-4D9D-B177-4E265174CA8AQ35134897-9956EBCE-F107-4A88-8CC7-68C2A78F7969Q35447934-9F3DD0DD-54DB-4523-81CB-4EFE5924595BQ35826752-D07C70D7-F549-4E33-8E0C-F3B1A0C007ADQ35863346-8B49C84B-58C8-4E5E-86E3-2DA1011B099FQ36175673-5BECA2F4-07A4-4F37-ADA2-742E8C4F4841Q36225449-1F6BAC2A-E4DE-41AD-B8B2-07D03450D003Q36581724-CB48ACD2-6D02-4084-9E28-9A7D461853C6Q37019430-3621938B-1A16-468A-9E7A-524F9F6E067CQ37061084-AC6BE27D-8FB0-4C3B-B068-DA73282901B4Q37086820-728EE2FD-06D3-42B1-B42F-C6DCAAEB4878Q37377550-1D8BA2A4-0F1B-4F37-A777-EB39F8F52C61Q37416593-08C6CF18-CC9D-4754-B3BE-06B59DD5FB43Q37426321-AF6E5A76-BBD5-47F8-8C55-D2B4B41C9F8BQ37603557-992720C0-01CF-425C-8A0F-E0D3FF8B0D89Q37691850-00BE5A2D-429F-4C24-95AD-D4D17CA675B3Q37736868-9701E457-0AEA-49D9-A86B-CBD298EB740FQ38059838-ED0C8498-8C73-4F8A-A9CF-0D4F1DD3F9E9Q38154804-432BB875-B742-4682-9358-F0D804A8F4B9Q38246639-C6C3224B-FF44-4A7C-A224-F43073B2E7CAQ38297557-5ECEDFFC-1D57-40F6-B100-D52C715A5C16Q38527924-9C296BA0-7804-4ECF-9FD4-1DA2D583B5BCQ38603362-4470C47F-4259-45F8-8584-C8B0EA602E19Q38802375-394E6462-3290-4CA9-B9E2-187F274D91E8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Engineering approaches to immunotherapy.
@en
type
label
Engineering approaches to immunotherapy.
@en
prefLabel
Engineering approaches to immunotherapy.
@en
P2860
P1476
Engineering approaches to immunotherapy
@en
P2093
Melody A Swartz
Sachiko Hirosue
P2860
P304
P356
10.1126/SCITRANSLMED.3003763
P407
P577
2012-08-01T00:00:00Z